Non-Hodgkin Lymphoma Refractory/ Relapsed
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
LTZ TherapeuticsLTZ-301
ImmunityBioCD19 t-haNK
Clinical Trials (2)
Total enrollment: 10 patients across 2 trials
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Start: Jan 2026Est. completion: Feb 2028
Phase 1Recruiting
Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma
Start: Aug 2024Est. completion: Mar 202710 patients
Phase 1Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3m ago
Office Administrator
SystImmune
3m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
17m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
17m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 10 patients
2 companies competing in this space